Abstract
Plasma cell leukemia (PCL) is rare and aggressive. Plasma cells from patients with PCL were examined using next-generation sequencing (NGS). We compared NGS data from 18 patients with PCL (peripheral blood, n = 10; bone marrow, n = 8) and 1742 multiple myeloma (MM) samples. Mutations of TP53, CCND1, and KRAS were commonly observed in both diseases. Alterations in DIS3 (17% vs 1%), CCND2 (22% vs 15%), PIK3R1 (6% vs 0%), and MAP3K1 (6% vs 2%) were more common in PCL than in MM (P < .05). Translocations occurred in 11 (61.1%) patients with PCL; IGH::CCND1 and IGH::MYC were more frequent in PCL than in MM (22% vs 14%, P = not significant and 11% vs 1%, P < .05, respectively). Druggable aberrations in BRAF, CCND1, PIK3R1, and RAS may be targeted in biomarker-driven therapeutic clinical trials.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1400-1404 |
| Number of pages | 5 |
| Journal | Blood Advances |
| Volume | 10 |
| Issue number | 4 |
| DOIs | |
| State | Published - Feb 24 2026 |
| Externally published | Yes |
ASJC Scopus subject areas
- Hematology
Fingerprint
Dive into the research topics of 'Plasma cell leukemia: genomic features and their potential relevance for exploring clinical actionability'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS